Business Wire

Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection

Share

Xlear has filed an Amended Answer in response to the U.S. Government’s lawsuit against the company. According to Nathan Jones, Xlear’s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of protection in fighting COVID-19, that our public health officials are ignoring; Second, it lays out in greater detail how the U.S. Government’s lawsuit is an effort to censor science that doesn’t comport with the Government’s vaccine-myopic, failing strategy to combat the disease; Third, it documents how experts, including Dr. Fauci, are increasingly saying the nose is the critical place to fight the virus.

Xlear’s Amended Answer provides two new studies that support the statements Xlear made about the use of its nasal spray as a potential additional layer of protection against COVID-19:

  • A new in vitro study found that use of a simple saline solution stops SAR-CoV2 viral replication in human lung tissue. Rafael R. G. Machado, Talita Glaser, Danielle B. Araujo, Lyvia Lintzmaier Petiz, Danielle B. L. Oliveira, Giuliana S. Durigon, Alessandra L. Leal, João Renato R. Pinho, Luis C. S. Ferreira, Henning Ulrich, Edison L. Durigon, and Cristiane Rodrigues Guzzo, ACS Pharmacology & Translational Science 2021 4 (5), 1514-1527, available at https://pubmed.ncbi.nlm.nih.gov/34651104/. Nate Jones, CEO of Xlear noted, “The Government agrees, Xlear is a saline nasal solution. This in vitro study documents that saline nasal hygiene helps stop COVID-19 from replicating in nasal tissue—which we know is where the virus typically grows and infects people.”
  • New in silico research determined that compounds of grapefruit seed extract (GSE) were effective inhibitors of the SARS-CoV-2 virus. Belmina Saric, et al., In silico analysis of selected components of grapefruit seed extract SARS-CoV-2 main protease, EuroBiotech J., 5 (special issue 1); 2021, 5. DOI: https://doi.org/10.2478/ebtj-2021-0015. Most importantly, these experts concluded natural GSE—which is a component of Xlear—was more effective than synthetic versions of the compound.

Jones continued: “These aren’t the Random Clinical Trials the Government is so focused on—but you can’t deny the mounting wall of evidence that nasal hygiene should be used as an additional layer of protection against COVID-19. Moreover, the Government recently announced that it won’t require Random Clinical Trials for the new variant vaccines—that requirement seems to only apply when it is convenient for the Government.”

Jones also noted that the SARS-CoV-2 variants are all strains of coronavirus, and experts have long recommended nasal hygiene to combat coronaviruses. “As a rule, prevention methods and symptom-reduction modalities (e.g., over the counter drugs, handwashing) are not variant specific; they are used against colds and flus on the whole, many caused by coronaviruses. One countermeasure that experts, including the US Government, recommend to fight the common cold, including coronavirus-infections, is nasal hygiene.” DeGeorge KC, Ring DJ, Dalrymple SN. Treatment of the Common Cold. Am Fam Physician. 2019 Sep 1;100(5):281-289. PMID: 31478634, reprinted by NIH as authority at https://pubmed.ncbi.nlm.nih.gov/31478634/ (“Treatments with proven effectiveness for cold symptoms [coronavirus infections] in adults include over-the-counter analgesics, zinc, nasal decongestants . . . The only established safe and effective treatments for children are . . . nasal saline irrigation . . .”). “It’s commonsense, something our Government’s response to COVID seems to be lacking,” Jones added.

As part of its efforts to silence Xlear, the Government asked the Utah Federal Court to preclude Xlear from filing the Amended Answer. The Federal Court ruled in Xlear’s favor. The Court’s ruling specifically noted: “The court shares some concern here, as expressed by Defendants, that the underlying purpose [in the Government’s motion to prevent Xlear’s Amended Answer] is to prevent discovery into disputed facts that may lend support to Defendants’ proposed amendments.” “In other words, the Government is doing everything they can stonewall us from shining a light on their failed COVID-19 response,” Jones added.

“A new more infectious and more dangerous variant is sweeping the nation. Infections are up. Hospitalizations are up. Deaths are up. At the same time, fewer and fewer people are willing to get vaccinated for the third, fourth, who knows how many times,” Jones noted. “It’s obvious we need a new, broader—'vaccine-plus’—approach. But rather than educate people, the Government is suing us in retaliation for talking about the science. I’m deeply afraid even telling the Court about these new studies will bring more Government retaliation, however in the face of the Government’s failure what choice is there. When science gives way to dogma, people suffer,” Jones concluded.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Xlear Media Relations
Nathan Jones
media@xlear.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BGI Preparing to Launch Improved Non-invasive Colorectal Cancer Screening Test, COLOTECT™ 3.029.11.2022 11:54:00 CET | Press release

COLOTECT™ 3.0 is a non-invasive colorectal cancer screening test developed by BGI, and will be launched in early 2023. BGI plans to release pre-clinical case-control data for COLOTECT™ 3.0 at the 2023 ASCO Gastrointestinal Cancers Symposium. The sensitivity for detecting CRC is 96.08%. The sensitivity for detecting advanced precancerous lesions (APL) is 52.5%, which is better than FIT products. COLOTECT™ 3.0 is a non-invasive colorectal cancer (CRC) self-sampling test that can detect the methylation status of exfoliated cell genes and the Fecal Occult Blood in the stool. It can help screen for colorectal cancer and advanced precancerous lesions (APL) even in the absence of active bleeding lesions. Colorectal cancer is the third most common cancer and the second deadly cancer worldwide. There were more than 1.9 million new cases of colorectal cancer in 2020. Older age, a history of bowel disease, a family history of related diseases, having type 2 diabetes, overweight or obesity, certai

Talkdesk Chosen as Wallbox Contact Center Solution29.11.2022 11:30:00 CET | Press release

Talkdesk®, Inc., a global cloud contact center leader for customer-obsessed companies, has been selected by Wallbox as its contact center solution provider. Wallbox selected the Talkdesk solution as part of a digital transformation for their contact center, improving both agent engagement and customer experience (CX). Wallbox is an EV charging and energy management company dedicated to changing the way the world uses energy. The company, headquartered in Barcelona, develops advanced EV charging systems that allow users to better manage their energy use and storage, redefining reliance on the energy grid. With offices worldwide, customers across 113 countries, and a geographically diverse workforce of over 1,000 people, Wallbox is committed to eliminating the barriers to EV adoption and helping to accelerate a global transition to more sustainable, efficient, and smart mobility. Talkdesk CX Cloud™, an end-to-end customer experience solution, will provide Wallbox with a modernized, cloud

Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug29.11.2022 11:26:00 CET | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) will manufacture and supply intermediates to Shionogi & Co., Ltd. (Headquarters: Chuo-ku, Osaka; Chief Executive Officer: Isao Teshirogi, Ph.D.) for use in Xocova®*1 (Ensitrelvir Fumaric Acid) Tablets 125mg, a drug for the treatment of SARS-Cov-2 infection. On November 22, Shionogi received emergency regulatory approval from the Ministry of Health, Labour and Welfare to manufacture and sell Xocova® tablets for treating SARS-Cov-2 infection. Shionogi recognized Kaneka for its long years of experience in manufacturing raw materials for medicines, and selected Kaneka as its main supplier for the drug's intermediates, which require GMP*2 management. The two companies have worked closely together for clinical development, approval application, and establishment of mass production supply chain. Kaneka will continue to improve its manufacturing systems and provide Shionogi with a stable supply of intermediates, play

Truvant Receives Procter & Gamble External Business Partner Excellence Award29.11.2022 10:00:00 CET | Press release

Packaging services provider Truvant is pleased to announce that it has received the Procter & Gamble External Business Partner Excellence Award in recognition of Truvants performance and long-standing relationship with the consumer goods giant. The External Business Partner Excellence Award was created by P&G to honor the contributions of those suppliers that have "gone above and beyond in delivering value" to the business. Truvant is the largest pure-play packaging services provider in the world, delivering manufacturing, packaging, and display solutions to the world’s leading brands. The company delivers high-quality, flexible, efficient, and sustainable packaging solutions that help brands get their products to the consumer in the most efficient way possible. Truvants solutions are designed to reduce costs, improve speed to market, create agility and manage complexity while reducing the impact on the environment. Procter & Gamble is one of the many long-standing clients that have be

Alpega’s Freight Exchange Teleroute Expands Its Ecosystem of Financial Solutions With FastPayment in Poland, Allowing Carriers to Cash out on Their Invoices Withing 2 Hours29.11.2022 10:00:00 CET | Press release

Long payment terms was already one of the most common issues faced in the transportation industry. In Poland specifically, the average time for carriers to receive their money after issuing an invoice, ranges from 45 to 60 days. However, with the unprecedented rising costs of fuel and transport operations, many carriers simply cannot afford to wait that long to receive payment for their delivered transport services. It becomes a threat for the business continuity and a rise in bankruptcies has been witnessed within the carrier community. FastPayment is a solution designed to overcome long payment terms. It is a safe solution and the entire process to request short-term financing for specific invoices is 100% online and without complex formalities, ensuring pay out in a matter of hours. The roll out of FastPayment in Poland is an extension of the service that was already operating successfully in Spain and Benelux. As a true pan-European freight exchange it is crucial to offer an ecosys

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom